thioctic acid has been researched along with Diabetic Nephropathies in 37 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the effects of combined administration of lipoic acid and pyridoxine on albuminuria, oxidative stress, blood pressure, serum advanced glycation end-products, nitric oxide (NO), and endothelin-1 in patients with diabetic nephropathy." | 9.17 | Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. ( Hedayati, M; Hosseinpanah, F; Nafar, M; Noori, N; Tabibi, H, 2013) |
| "This study was designed to investigate the effects of combined administration of lipoic acid and pyridoxine on albuminuria, oxidative stress, blood pressure, serum advanced glycation end-products, nitric oxide (NO), and endothelin-1 in patients with diabetic nephropathy." | 5.17 | Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy. ( Hedayati, M; Hosseinpanah, F; Nafar, M; Noori, N; Tabibi, H, 2013) |
| " Compared with control rats, D developed increased urinary excretion of albumin and transforming growth factor beta, renal insufficiency, glomerular mesangial matrix expansion, and glomerulosclerosis in association with depletion of glutathione and accumulation of malondialdehyde in renal cortex." | 3.71 | Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. ( Craven, PA; DeRubertis, FR; Liachenko, J; Melhem, MF, 2002) |
| "This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN." | 3.11 | Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial. ( Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022) |
| "The aim of this study was to compare curative effects of valsartan alone or combined with alpha-lipoic acid (ALA) on inflammatory cytokine indices including hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α) and renal function indices including urinary albumin excretion rate (UAER), β2-microglobulin (β2-MG) and cystatin C (Cys C) of patients with early-stage diabetic kidney disease (DKD)." | 2.90 | Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease. ( Jiang, Z; Li, X; Meng, F; Tan, Z, 2019) |
| " The purpose of this study was to evaluate the efficacy of valsartan combined with α-lipoic acid on renal function in patients with DN." | 2.72 | Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. ( Cai, J; Jiang, D; Sun, F, 2021) |
| "Forty-nine patients (34 with Type 1 diabetes, 15 with Type 2 diabetes) had no antioxidant treatment and served as a control group." | 2.70 | Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. ( Amiral, J; Borcea, V; Ehret, T; Gehrke, S; Henkels, M; Hofmann, M; Isermann, B; Morcos, M; Nawroth, PP; Schiekofer, S; Tritschler, H; Wahl, P; Ziegler, R, 2001) |
| " Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated." | 1.91 | Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. ( Su, F; Xia, Q, 2023) |
| "Polyneuropathies were specified as toxic/metabolic with the prevalence of a demyelinating component within the main disease in 18 (67%) patients." | 1.38 | [Demyelinating polyneuropathies in patients with diabetes mellitus and chronic alcoholic intoxication]. ( Kovrazhkina, EA, 2012) |
| "Thioctic acid treatment was discontinued 2 days after admission." | 1.37 | Thioctic acid-induced acute cholestatic hepatitis. ( Castiglioni, T; Ridruejo, E; Silva, MO, 2011) |
| "Twenty-eight patients, 17 women and 11 men, aged 40-70 years, with distal sensory-motor diabetic neuropathy of the lower extremities were treated with berlition, an alpha-lipoic acid preparation, in dosage 600 mg daily during 3 months." | 1.35 | [Implication of alpha-lipoic acid preparations in the treatment of diabetic neuropathy]. ( Al'-Zamil', MKh; Brezheva, EV, 2008) |
| "We hypothesized that streptozotocin diabetes in rats and mice would result in an early reduction in podocyte density and that this reduction would be prevented by antioxidants." | 1.33 | Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. ( Brosius, FC; Saha, J; Siu, B; Smoyer, WE; Sullivan, KA, 2006) |
| "Patients with diabetic nephropathy showed higher NF-kappaB binding activity in Electrophoretic Mobility Shift Assays and stronger immunohistological staining for activated NF-kappaBp65 than patients without renal complications." | 1.30 | Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. ( Abdel Khalek, AK; Amiral, J; Bierhaus, A; Borcea, V; Henkels, M; Hofmann, MA; Isermann, B; Joswig, M; Kanitz, M; Morcos, M; Nawroth, PP; Ritz, E; Schiekofer, S; Treusch, A; Tritschler, H; Wahl, P; Weiss, T; Ziegler, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.70) | 18.7374 |
| 1990's | 3 (8.11) | 18.2507 |
| 2000's | 14 (37.84) | 29.6817 |
| 2010's | 13 (35.14) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, F | 1 |
| Jiang, D | 1 |
| Cai, J | 1 |
| Dugbartey, GJ | 1 |
| Alornyo, KK | 1 |
| N'guessan, BB | 1 |
| Atule, S | 1 |
| Mensah, SD | 1 |
| Adjei, S | 1 |
| Jiao, S | 1 |
| Dong, Y | 1 |
| Chang, X | 1 |
| Wu, Y | 1 |
| Li, H | 1 |
| Zhang, HF | 1 |
| Liu, HM | 1 |
| Xiang, JY | 1 |
| Zhou, XC | 1 |
| Wang, D | 1 |
| Chen, RY | 1 |
| Tan, WL | 1 |
| Liang, LQ | 1 |
| Liu, LL | 1 |
| Shi, MJ | 1 |
| Zhang, F | 1 |
| Xiao, Y | 1 |
| Zhou, YX | 1 |
| Zhang, T | 1 |
| Tang, L | 1 |
| Guo, B | 1 |
| Wang, YY | 1 |
| Su, F | 1 |
| Xia, Q | 1 |
| Jiang, Z | 1 |
| Tan, Z | 1 |
| Meng, F | 1 |
| Li, X | 1 |
| Kayhan Kuştepe, E | 1 |
| Bahar, L | 1 |
| Zayman, E | 1 |
| Sucu, N | 1 |
| Gül, S | 1 |
| Gül, M | 1 |
| Noori, N | 1 |
| Tabibi, H | 1 |
| Hosseinpanah, F | 1 |
| Hedayati, M | 1 |
| Nafar, M | 1 |
| Safa, J | 1 |
| Ardalan, MR | 1 |
| Rezazadehsaatlou, M | 1 |
| Mesgari, M | 1 |
| Mahdavi, R | 1 |
| Jadid, MP | 1 |
| Mao, ZM | 1 |
| Shen, SM | 1 |
| Wan, YG | 1 |
| Sun, W | 1 |
| Chen, HL | 1 |
| Huang, MM | 1 |
| Yang, JJ | 1 |
| Wu, W | 1 |
| Tang, HT | 1 |
| Tang, RM | 1 |
| Sun, H | 1 |
| Yao, W | 1 |
| Tang, Y | 1 |
| Zhuang, W | 1 |
| Wu, D | 1 |
| Huang, S | 1 |
| Sheng, H | 1 |
| Lee, SJ | 1 |
| Kang, JG | 1 |
| Ryu, OH | 1 |
| Kim, CS | 1 |
| Ihm, SH | 1 |
| Choi, MG | 1 |
| Yoo, HJ | 1 |
| Kim, DS | 1 |
| Kim, TW | 1 |
| Kanter, M | 1 |
| Sen, S | 1 |
| Donmez, S | 1 |
| Aktas, C | 1 |
| Ustundag, S | 1 |
| Erboga, M | 1 |
| Li, XZ | 1 |
| Yan, HD | 1 |
| Wang, J | 1 |
| Ridruejo, E | 1 |
| Castiglioni, T | 1 |
| Silva, MO | 1 |
| Huk-Kolega, H | 1 |
| Skibska, B | 1 |
| Kleniewska, P | 1 |
| Piechota, A | 1 |
| Michalski, Ł | 1 |
| Goraca, A | 1 |
| Bertolotto, F | 1 |
| Massone, A | 1 |
| Kovrazhkina, EA | 1 |
| Okuyucu, S | 1 |
| Kocer, A | 1 |
| Eryilmaz, M | 1 |
| Kocaman, G | 1 |
| Mıcılı, SC | 1 |
| Ergur, BU | 1 |
| Ozoğul, C | 1 |
| Sarıoğlu, S | 1 |
| Bağrıyanık, HA | 1 |
| Tuğyan, K | 1 |
| Pekcetin, C | 1 |
| Sonmez, U | 1 |
| Tekmen, I | 1 |
| Erbil, G | 1 |
| Akdoğan, GG | 1 |
| Ozyurt, D | 1 |
| Buldan, Z | 1 |
| Nascimento, NR | 1 |
| Costa-e-Forti, A | 1 |
| Peter, AA | 1 |
| Fonteles, MC | 1 |
| Alderson, NL | 1 |
| Chachich, ME | 1 |
| Frizzell, N | 1 |
| Canning, P | 1 |
| Metz, TO | 1 |
| Januszewski, AS | 1 |
| Youssef, NN | 1 |
| Stitt, AW | 1 |
| Baynes, JW | 1 |
| Thorpe, SR | 1 |
| Bhatti, F | 1 |
| Mankhey, RW | 1 |
| Asico, L | 1 |
| Quinn, MT | 1 |
| Welch, WJ | 1 |
| Maric, C | 1 |
| Siu, B | 1 |
| Saha, J | 1 |
| Smoyer, WE | 1 |
| Sullivan, KA | 1 |
| Brosius, FC | 1 |
| Chang, JW | 1 |
| Lee, EK | 1 |
| Kim, TH | 1 |
| Min, WK | 1 |
| Chun, S | 1 |
| Lee, KU | 1 |
| Kim, SB | 1 |
| Park, JS | 1 |
| Oksala, NK | 1 |
| Lappalainen, J | 1 |
| Laaksonen, DE | 1 |
| Khanna, S | 1 |
| Kaarniranta, K | 1 |
| Sen, CK | 1 |
| Atalay, M | 1 |
| Tang, J | 1 |
| Wingerchuk, DM | 1 |
| Crum, BA | 1 |
| Rubin, DI | 1 |
| Demaerschalk, BM | 1 |
| Winiarska, K | 1 |
| Malinska, D | 1 |
| Szymanski, K | 1 |
| Dudziak, M | 1 |
| Bryla, J | 1 |
| Liu, F | 1 |
| Zhang, Y | 1 |
| Yang, M | 1 |
| Liu, B | 1 |
| Shen, YD | 1 |
| Jia, WP | 1 |
| Xiang, KS | 1 |
| Al'-Zamil', MKh | 1 |
| Brezheva, EV | 1 |
| Kähler, W | 1 |
| Kuklinski, B | 1 |
| Rühlmann, C | 1 |
| Plötz, C | 1 |
| Hofmann, MA | 1 |
| Schiekofer, S | 2 |
| Isermann, B | 2 |
| Kanitz, M | 1 |
| Henkels, M | 2 |
| Joswig, M | 1 |
| Treusch, A | 1 |
| Morcos, M | 2 |
| Weiss, T | 1 |
| Borcea, V | 2 |
| Abdel Khalek, AK | 1 |
| Amiral, J | 2 |
| Tritschler, H | 2 |
| Ritz, E | 1 |
| Wahl, P | 2 |
| Ziegler, R | 2 |
| Bierhaus, A | 1 |
| Nawroth, PP | 2 |
| Ruhnau, KJ | 1 |
| Meissner, HP | 1 |
| Finn, JR | 1 |
| Reljanovic, M | 1 |
| Lobisch, M | 1 |
| Schütte, K | 1 |
| Nehrdich, D | 1 |
| Tritschler, HJ | 1 |
| Mehnert, H | 1 |
| Ziegler, D | 1 |
| Melhem, MF | 2 |
| Craven, PA | 2 |
| Derubertis, FR | 2 |
| Gehrke, S | 1 |
| Ehret, T | 1 |
| Hofmann, M | 1 |
| Liachenko, J | 1 |
| Sauer, H | 1 |
| Böninger, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy[NCT01313117] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01313117)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Alpha Lipoic Acid | 9 |
Based on acceptable adverse event (AE) profile and continual reassessment method dose escalation. (NCT01313117)
Timeframe: 4 months
| Intervention | mg (Number) |
|---|---|
| Alpha Lipoic Acid | 500 |
(NCT01313117)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Alpha Lipoic Acid | 7 |
2 reviews available for thioctic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis.
Topics: Antihypertensive Agents; Antioxidants; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Ki | 2021 |
[Role of lipoic acid in health and disease].
Topics: Antioxidants; Chelating Agents; Diabetic Nephropathies; Heavy Metal Poisoning; Humans; Mycoses; Pois | 2011 |
12 trials available for thioctic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Dia | 2022 |
Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; China; Cytokines; Diabetic Nephropathies; Drug The | 2019 |
Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Arginine; Blood Pressure; Creatinine; Diabetic Nephropathies; Double-Blind | 2013 |
Effects of alpha lipoic acid supplementation on serum levels of IL-8 and TNF-α in patient with ESRD undergoing hemodialysis.
Topics: Adult; Aged; Antioxidants; Diabetic Nephropathies; Dietary Supplements; Double-Blind Method; Female; | 2014 |
Urinary exosomes as a novel biomarker for evaluation of α-lipoic acid's protective effect in early diabetic nephropathy.
Topics: Aged; Biomarkers; Diabetic Nephropathies; Exosomes; Female; Humans; Male; Middle Aged; Protective Ag | 2017 |
Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy.
Topics: Aged; Ambulatory Care; Antioxidants; Diabetic Nephropathies; Female; Humans; Male; Neural Conduction | 2012 |
Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
Topics: Adult; Antioxidants; Arginine; Biomarkers; C-Reactive Protein; Cholesterol; Chromatography, High Pre | 2007 |
Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy.
Topics: Administration, Oral; Aged; Antioxidants; Diabetic Nephropathies; Dose-Response Relationship, Drug; | 2007 |
[Curative effect of alpha-lipoic acid on peripheral neuropathy in type 2 diabetes: a clinical study].
Topics: Aged; Antioxidants; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2007 |
[Diabetes mellitus--a free radical-associated disease. Results of adjuvant antioxidant supplementation].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropat | 1993 |
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; | 1999 |
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; | 1999 |
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; | 1999 |
Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.
Topics: Aged; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; | 1999 |
Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study.
Topics: Albuminuria; Antioxidants; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2001 |
23 other studies available for thioctic acid and Diabetic Nephropathies
| Article | Year |
|---|---|
Supplementation of conventional anti-diabetic therapy with alpha-lipoic acid prevents early development and progression of diabetic nephropathy.
Topics: Animals; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabe | 2022 |
Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating RXRα expression and activation.
Topics: Animals; beta Catenin; Cystic Fibrosis Transmembrane Conductance Regulator; Diabetes Mellitus, Type | 2023 |
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
A light microscopic investigation of the renoprotective effects of α-lipoic acid and α-tocopherol in an experimental diabetic rat model.
Topics: alpha-Tocopherol; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ma | 2020 |
Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
Topics: Abelmoschus; Animals; Antioxidants; Capsules; Diabetes Mellitus, Experimental; Diabetic Nephropathie | 2015 |
Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Blotting, W | 2009 |
Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats.
Topics: Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Immuno | 2010 |
[Extract of Ginkgo biloba and alpha-lipoic acid attenuate advanced glycation end products accumulation and RAGE expression in diabetic nephropathy rats].
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ginkgo biloba; Glyca | 2011 |
Thioctic acid-induced acute cholestatic hepatitis.
Topics: Antioxidants; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, | 2011 |
[Demyelinating polyneuropathies in patients with diabetes mellitus and chronic alcoholic intoxication].
Topics: Acute Disease; Alcoholism; Antioxidants; Diabetic Nephropathies; Electromyography; Humans; Polyneuro | 2012 |
Thioctacid is effective for neuropathy symptoms and hyperglycemia control without pronounced electromyographic changes.
Topics: Aged; Antioxidants; Diabetic Nephropathies; Electromyography; Female; Humans; Male; Middle Aged; Neu | 2012 |
Effects of lipoic acid in an experimentally induced hypertensive and diabetic rat model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypertensi | 2013 |
Free radical scavengers improve the impaired endothelium-dependent responses in aorta and kidneys of diabetic rabbits.
Topics: Animals; Aorta, Thoracic; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Vascular; Free | 2003 |
Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, E | 2004 |
Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney.
Topics: Albuminuria; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephrop | 2005 |
Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment.
Topics: Animals; Antioxidants; Cell Count; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; Mi | 2006 |
Alpha-lipoic Acid modulates heat shock factor-1 expression in streptozotocin-induced diabetic rat kidney.
Topics: Analysis of Variance; Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropa | 2007 |
Lipoic acid ameliorates oxidative stress and renal injury in alloxan diabetic rabbits.
Topics: Animals; Antioxidants; Blood Glucose; Creatine; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2008 |
[Implication of alpha-lipoic acid preparations in the treatment of diabetic neuropathy].
Topics: Adult; Aged; Antioxidants; Diabetic Nephropathies; Dose-Response Relationship, Drug; Electromyograph | 2008 |
Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB.
Topics: Adult; Albuminuria; Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nep | 1999 |
Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus.
Topics: Animals; Antioxidants; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dietary Su | 2001 |
Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes.
Topics: Albuminuria; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephrop | 2002 |
[What is reliable in the therapy of diabetes mellitus?].
Topics: Carbutamide; Chlorpropamide; Chronic Disease; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nep | 1970 |